Bicara Therapeutics Inc. (BCAX) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Ficerafusp Alfa Overall Survival at Three Years | 31.00 percent | FY2026-Q2 |
| Complete Response Rate | 26.00 percent | FY2025-Q4 |
| Confirmed Overall Response Rate | 48.00 percent | FY2025-Q4 |
| Median Depth of Response at 24 Weeks | 100.00 percent | FY2025-Q4 |
| Confirmed Overall Response Rate, 2,000-Milligram Every-Two-Weeks Cohort | 48.00 percent | FY2026-Q1 |
| Global Active Sites in Fortify HN01 | 200.00 | FY2026-Q2 |
| Patients Reported Across Phase Ib Cohorts | 90.00 | FY2026-Q2 |
| Depth of Response at 24 Weeks | 11.00 | FY2025-Q4 |
| Reportable operating income | -59.95M | FY2026-Q2 |
| Net Proceeds Raised in Public Offering | 161.8M | FY2026-Q1 |
Back to BCAX overview · BCAX earnings · BCAX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.